Skip to main content
Atrás
AKBLF logo

ALK-Abelló A/S

Calidad de datos: 100%
Sobreventa
AKBLF
OTC Healthcare Biotechnology
$32.18
$0.00 (0.00%)
Cap. Mercado: 6.48B
Rango del Día
$32.18 $36.10
Rango de 52 Semanas
$19.90 $36.14
Volumen
100
Promedio 50D / 200D
$35.21 / $32.30
Cierre Anterior
$32.18

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 5.4 0.4
P/B 1.0 2.9
ROE % 20.2 3.8
Net Margin % 19.0 3.9
Rev Growth 5Y % 12.6 10.0
D/E 0.1 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $0.00
$0.00 – $0.00
 10 B 0
FY2029 $9.86
$9.77 – $9.95
 10 B 1
FY2028 $8.00
$7.92 – $8.07
 9 B 1

Puntos Clave

Revenue grew 12.61% annually over 5 years — strong growth
Earnings grew 46.54% over the past year
ROE of 20.24% indicates high profitability
Net margin of 18.96% shows strong profitability
Debt/Equity of 0.07 — conservative balance sheet
Generating 1.54B in free cash flow

Crecimiento

Revenue Growth (5Y)
12.61%
Revenue (1Y)13.74%
Earnings (1Y)46.54%
FCF Growth (3Y)131.05%

Calidad

Return on Equity
20.24%
ROIC18.17%
Net Margin18.96%
Op. Margin26.35%

Seguridad

Debt / Equity
0.07
Current Ratio3.38
Interest Coverage72.30

Valoración

P/E Ratio
5.42
P/B Ratio1.01
EV/EBITDA3.41
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13.74% Revenue Growth (3Y) 14.26%
Earnings Growth (1Y) 46.54% Earnings Growth (3Y) 56.76%
Revenue Growth (5Y) 12.61% Earnings Growth (5Y) 52.82%
Profitability
Revenue (TTM) 6.30B Net Income (TTM) 1.19B
ROE 20.24% ROA 13.05%
Gross Margin 65.87% Operating Margin 26.35%
Net Margin 18.96% Free Cash Flow (TTM) 1.54B
ROIC 18.17% FCF Growth (3Y) 131.05%
Safety
Debt / Equity 0.07 Current Ratio 3.38
Interest Coverage 72.30 Dividend Yield 0.00%
Valuation
P/E Ratio 5.42 P/B Ratio 1.01
P/S Ratio 1.03 PEG Ratio 0.91
EV/EBITDA 3.41 Dividend Yield 0.00%
Market Cap 6.48B Enterprise Value 5.66B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.30B 5.54B 4.82B 4.51B 3.92B
Net Income 1.19B 815.00M 486.00M 335.00M 219.00M
EPS (Diluted) 5.41 3.68 2.20 1.51 0.99
Gross Profit 4.15B 3.55B 3.04B 2.79B 2.40B
Operating Income 1.66B 1.09B 666.00M 470.00M 292.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9.15B 8.25B 6.73B 6.31B 5.83B
Total Liabilities 2.72B 2.87B 2.28B 2.32B 2.35B
Shareholders' Equity 6.43B 5.37B 4.45B 3.99B 3.48B
Total Debt 418.00M 1.19B 765.00M 696.00M 710.00M
Cash & Equivalents 1.24B 589.00M 474.00M 221.00M 194.00M
Current Assets 4.48B 3.29B 2.97B 2.65B 2.40B
Current Liabilities 1.33B 1.95B 1.31B 1.40B 1.39B

Puntuaciones de Estrategias

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#591 of 1024
41
Custom Capital Light Compounder
#85 of 213
46
Custom Contrarian Investing (David Dreman)
#129 of 658
52
Growth Growth Investing (Philip Fisher)
#149 of 154
15
Value Value Investing (Warren Buffett)
#148 of 195
33
Custom Balanced Risk
#98 of 148
42
Custom Lower Risk
#126 of 136
28

Actividad Reciente

Entró Cash Flow Compounder
Mar 24, 2026
Entró Capital Light Compounder
Mar 24, 2026
Entró Contrarian Investing (David Dreman)
Mar 24, 2026
Entró Growth Investing (Philip Fisher)
Mar 24, 2026
Entró Value Investing (Warren Buffett)
Mar 24, 2026
Entró Balanced Risk
Mar 24, 2026
Entró Lower Risk
Mar 24, 2026